


In the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims:

1. (Original) A compound of Formula (I),




Formula (I)

wherein

A represents a direct bond or optionally substituted C₁₋₅alkylene;

B is a group of Formula (II):



Formula (II);


wherein at position (a) Formula (II) is attached to the nitrogen atom and the group **X** is attached to **R**⁸;

M is -(CH₂)₀₋₂-O-;

R¹ represents hydrogen; optionally substituted C₁₋₈alkyl; or (CH₂)_b-**R**^a,

wherein **R**^a represents C₃₋₈cycloalkyl and **b** is zero or an integer from 1 to 6;


R^2 represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR^3R^{3a} , optionally substituted C_{1-8} alkyl, optionally substituted C_{1-8} alkoxy or halo;
 R^3 and R^{3a} are independently selected from hydrogen; optionally substituted C_{1-8} alkyl and optionally substituted aryl;
 R^5 is selected from an optionally substituted 3 to 8 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**; **III-g**, **III-h**, **III-i** or: **III-j**;



wherein **het** represents an optionally substituted 3 to 8 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R^6 and R^{6a} , are independently selected from hydrogen and optionally substituted C_{1-8} alkyl; or R^6 and R^{6a} together represent carbonyl;

R^7 represents hydrogen or optionally substituted C_{1-8} alkyl;

or R^6  together from an optionally substituted 3- to 8-membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and R^{6a} represents hydrogen and optionally substituted C_{1-8} alkyl;

X and R^8 are selected from:

- (i) X represents N and R^8 is selected from:
cyano, hydrogen, hydroxy, $-O-R^b$, $-NR^bR^c$, $-C(O)O-R^b$, $-CONR^bR^c$
or $NH-C(O)-R^b$, where R^b and R^c are independently selected from
hydrogen and C_{1-4} alkyl optionally substituted with hydroxy, amino,
 $N-C_{1-4}$ alkylamino, N,N -di- C_{1-4} alkylamino, $HO-C_{2-4}$ alkyl-NH- or
 $HO-C_{2-4}$ alkyl-N(C_{1-4} alkyl)-;
- (ii) X represents CH and R^8 represents NO_2 ; and
- (iii) X- R^8 represents $-O-$;

R^{11} is a group of the formula: $N(R^9R^{10})$ wherein R^9 represents hydrogen, aryl,
an optionally substituted 3- to 10 membered heterocyclic ring or
optionally-substituted C_{1-8} alkyl and R^{10} represents hydrogen or optionally
substituted C_{1-8} alkyl; or


the structure $N(R^9R^{10})$ represents an optionally-substituted 3- to 10
membered heterocyclic ring optionally containing from 1 to 3 further
heteroatoms independently selected from O, N and S;

R^{12} and R^{12a} are independently selected from hydrogen or optionally
substituted C_{1-8} alkyl; or R^{12} and R^{12a} together with the carbon to which they
are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;
 R^{13} and R^{14} are selected from:

- (i) R^{13} is selected from hydrogen; optionally substituted C_{1-8} alkyl;
optionally substituted aryl; $-R^d-Ar$, where R^d represents C_{1-8} alkylene
and Ar represents optionally substituted aryl; and optionally

substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and R^{14} is selected from hydrogen; optionally substituted C_{1-8} alkyl and optionally substituted aryl;

- (ii) where R^5 represents a group of formula **III-a**, **III-b** or **III-i**, then the group $NR^{13}(-R^{14})$ represents an optionally substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or


- (iii) where R^5 represents structure **III-e**, then the group  represents an optionally substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S; or a salt, pro-drug or solvate thereof.

2. (Original) A compound according to Claim 1 wherein R^9 represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8} alkyl and R^{10} represents hydrogen or optionally substituted C_{1-8} alkyl wherein the optional substituents on aryl, the heterocyclic ring and C_{1-8} alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3 to 8 membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$, $-S(O_{0-2})R^b$, wherein R^b and R^c are as defined in Claim 1.

3. (Original) A compound according to Claim 2 wherein R^9 is a C_{1-6} alkyl group substituted by pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl,

benztriazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl or 2-azetynyl, each of which is optionally substituted.

4. (Original) A compound according to Claim 1 wherein the structure $N(R^9R^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.
5. (Original) A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from R^{15} wherein R^{15} is selected from optionally substituted aryl, an optionally substituted 3 to 10 membered heterocyclic ring or optionally substituted C_{1-4} alkyl wherein the optional substituents on aryl, a heterocyclic ring or C_{1-4} alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3 to 8 membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$, $-S(O_{0-2})R^b$, wherein R^b and R^c are as defined in Claim 1.
6. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R^5 is selected from a group of formula **III-a**, **III-g**, **III-h**, **III-i** or **III-j**:



7. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein **X** and **R⁸** are selected from
 - (a) **X** represents N and **R⁸** represents cyano or $-\text{C}(\text{O})\text{O}-\text{R}^b$; or
 - (b) **X** represents N and **R⁸** represents hydrogen.
8. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein **R²** is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR^eR^f , optionally substituted C_{1-8} alkyl, optionally substituted C_{1-8} alkoxy or halo wherein **R^e** and **R^f** are independently selected from hydrogen, C_{1-6} alkyl or aryl.
9. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein **R¹** is hydrogen.
10. (Original) The compound:
 3-[2,2-dimethyl-3-oxo-3-(azabicyclo[2.2.1]heptan-7-yl)propyl]-
 4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-yl
 carboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole;

or a salt, pro-drug or solvate thereof.


11. (Cancelled)

12. (Currently amended) A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to claim 1 ~~any one of Claims 1 to 10~~ and a pharmaceutically acceptable diluent or carrier.


13. (Currently amended) A method of treating and/or preventing a sex hormone related condition in a patient, the method comprising administering ~~Use of a compound according to claim 1, or salt, pro-drug or solvate thereof, according to to a patient. any one of Claims 1 to 10, in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient.~~

14. (Currently amended) A process of producing a compound, or salt, pro-drug or solvate thereof, according to claim 1 ~~any one of Claims 1 to 10~~, wherein the process comprises a reaction step selected from any one of steps (a) to (f):-


- (a) for compounds wherein **X** is N and **R⁸** is CN, reaction of a compound of formula **XXXII** as follows




- (b) for compounds wherein **X** is N and **R**⁸ is hydrogen, cleavage of the cyano group of compound of formula **XXXIII** in the presence of acid to produce compound of formula **XXXIV**




- (c) for compounds wherein **X** is CH and **R**⁸ is NO₂, reaction of compound of formula **XXXV** as follows




- (d) for compounds where $X-R^8$ is O, reaction of compound of formula XXXVII as follows



- (e) for compounds where $X-R^8$ is O, reaction of compound of formula XXXIX as follows



- (f) to form a compound wherein X is nitrogen reaction of a compound of formula XXXXI as follows



and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate.